Fate Therapeutics, Inc. (FATE)Â
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
FATE Insider Trading Activity
FATE Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $668,580 | 1 | 17 |
Sells | $608,059 | 5 | 83 |
Related Transactions
| Redmile Group, LLC | 1 | $668,580 | 1 | $573,943 | $94,636 | |
| Xu Yuan | director | 0 | $0 | 1 | $2,678 | $-2,678 |
| TAHL CINDY | See Remarks | 0 | $0 | 1 | $8,764 | $-8,764 |
| Bressi Jerome Charles | See Remarks | 0 | $0 | 1 | $9,269 | $-9,269 |
| Valamehr Bahram | President and CEO | 0 | $0 | 1 | $13,406 | $-13,406 |
About Fate Therapeutics, Inc.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Insider Activity of Fate Therapeutics, Inc.
Over the last 12 months, insiders at Fate Therapeutics, Inc. have bought $668,580 and sold $608,059 worth of Fate Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Fate Therapeutics, Inc. have bought $27.85M and sold $21.53M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Redmile Group, LLC () — $668,580.
The last purchase of 397,964 shares for transaction amount of $668,580 was made by Redmile Group, LLC () on 2024‑12‑20.
List of Insider Buy and Sell Transactions, Fate Therapeutics, Inc.
| 2025-01-10 | Sale | Valamehr Bahram | President and CEO | 8,705 0.008% | $1.54 | $13,406 | -14.29% | |
| 2025-01-10 | Sale | TAHL CINDY | See Remarks | 5,654 0.0052% | $1.55 | $8,764 | -14.29% | |
| 2025-01-10 | Sale | Bressi Jerome Charles | See Remarks | 5,980 0.0055% | $1.55 | $9,269 | -14.29% | |
| 2024-12-20 | Sale | Redmile Group, LLC | 341,633 0.2991% | $1.68 | $573,943 | -22.62% | ||
| 2024-12-20 | Redmile Group, LLC | 397,964 0.3484% | $1.68 | $668,580 | -22.62% | |||
| 2024-08-06 | Sale | Xu Yuan | director | 633 0.0005% | $4.23 | $2,678 | -44.64% | |
| 2024-03-04 | Sale | Dulac Edward J III | Chief Financial Officer | 2,447 0.0027% | $7.77 | $19,013 | -51.55% | |
| 2024-01-29 | Sale | Dulac Edward J III | Chief Financial Officer | 1,849 0.0017% | $5.00 | $9,245 | -36.19% | |
| 2024-01-09 | Sale | Wolchko J Scott | President and CEO | 14,391 0.0145% | $4.37 | $62,889 | -14.74% | |
| 2024-01-09 | Sale | Valamehr Bahram | Chief R&D Officer | 11,271 0.0114% | $4.38 | $49,367 | -14.74% | |
| 2024-01-09 | Sale | TAHL CINDY | General Counsel and Secretary | 10,874 0.0109% | $4.37 | $47,519 | -14.74% | |
| 2024-01-09 | Sale | Dulac Edward J III | Chief Financial Officer | 7,028 0.0071% | $4.37 | $30,712 | -14.74% | |
| 2024-01-02 | Sale | Dulac Edward J III | Chief Financial Officer | 5,182 0.0052% | $3.66 | $18,966 | +2.57% | |
| 2023-12-26 | Redmile Group, LLC | 44,630 0.0455% | $3.72 | $166,024 | +2.15% | |||
| 2023-12-18 | Sale | Dulac Edward J III | Chief Financial Officer | 1,585 0.0018% | $3.50 | $5,548 | +20.63% | |
| 2023-11-09 | Sale | TAHL CINDY | General Counsel and Secretary | 24,363 0.0278% | $2.40 | $58,471 | +78.40% | |
| 2023-08-18 | Sale | Dulac Edward J III | Chief Financial Officer | 4,718 0.0048% | $2.80 | $13,210 | +33.09% | |
| 2023-08-04 | Sale | Xu Yuan | director | 632 0.0006% | $3.71 | $2,345 | -1.34% | |
| 2023-07-05 | Sale | Dulac Edward J III | Chief Financial Officer | 5,182 0.0053% | $4.83 | $25,029 | -23.46% | |
| 2023-07-05 | Sale | Powl Brian T. | Chief Commercial Officer | 3,854 0.0039% | $4.87 | $18,769 | -23.46% |
Insider Historical Profitability
| Redmile Group, LLC | 12884277 11.2431% | $11.77M | 9 | 2 | +11.38% | |
| Valamehr Bahram | President and CEO | 349364 0.3049% | $319,283.76 | 0 | 18 | |
| TAHL CINDY | See Remarks | 336707 0.2938% | $307,716.53 | 0 | 26 | |
| Bressi Jerome Charles | See Remarks | 270203 0.2358% | $246,938.52 | 0 | 1 | |
| Xu Yuan | director | 8669 0.0076% | $7,922.60 | 0 | 3 | |
| NELSEN ROBERT | 2473188 2.1582% | $2.26M | 1 | 0 | <0.0001% | |
| ARCH VENTURE FUND VI LP | 10 percent owner | 2473188 2.1582% | $2.26M | 1 | 0 | <0.0001% |
| VENROCK ASSOCIATES V LP | 10 percent owner | 2473187 2.1582% | $2.26M | 1 | 0 | <0.0001% |
| Polaris Venture Management Co. V, L.L.C. | 10 percent owner | 2473186 2.1582% | $2.26M | 1 | 0 | <0.0001% |
| RASTETTER WILLIAM H | director | 459272 0.4008% | $419,728.68 | 2 | 0 | +1.02% |
| Wolchko J Scott | President and CEO | 371248 0.324% | $339,283.55 | 0 | 37 | |
| MENDLEIN JOHN | director | 282770 0.2468% | $258,423.50 | 3 | 2 | <0.0001% |
| Chu Yu-Waye | Chief Medical Officer | 140676 0.1228% | $128,563.80 | 0 | 6 | |
| Plavsic Mark | Chief Technical Officer | 123705 0.1079% | $113,054.00 | 0 | 2 | |
| Dulac Edward J III | Chief Financial Officer | 101479 0.0886% | $92,741.66 | 0 | 13 | |
| Shoemaker Daniel D | Chief Scientific Officer | 73020 0.0637% | $66,732.98 | 0 | 13 | |
| COUGHLIN TIMOTHY | 57632 0.0503% | $52,669.88 | 1 | 1 | +11.55% | |
| Powl Brian T. | Chief Commercial Officer | 41146 0.0359% | $37,603.33 | 0 | 1 | |
| Storgard Chris | Chief Medical Officer | 37593 0.0328% | $34,356.24 | 1 | 0 | +11.55% |
| Nashat Amir | director | 7539 0.0066% | $6,889.89 | 1 | 20 | <0.0001% |
| Flynn Peter D | See remarks | 4039 0.0035% | $3,691.24 | 0 | 8 | |
| HERSHBERG ROBERT | 2009 0.0018% | $1,836.03 | 0 | 1 | ||
| Agarwal Shefali | 1840 0.0016% | $1,681.58 | 0 | 2 | ||
| Jooss Karin | 1198 0.001% | $1,094.85 | 0 | 1 | ||
| Weyer Christian | See remarks | 0 0% | $0 | 0 | 2 |
Historical Insider Profitability vs. Competitors
$12,784,645 | 193 | 20.49% | $106.05M | |
$4,919,189 | 138 | 5.22% | $101.74M | |
$22,597,521 | 91 | 4.59% | $99.07M | |
$36,079,815 | 31 | 43.23% | $103.59M | |
Fate Therapeutics, Inc. (FATE) | $294,424,120 | 20 | 1.33% | $104.73M |
$111,692,551 | 18 | 13.51% | $103.5M | |
$32,972,199 | 16 | -10.77% | $104.01M | |
$178,593,887 | 15 | -14.86% | $100.86M | |
$932,835 | 14 | -19.33% | $106.09M | |
$398,999,793 | 13 | -14.11% | $105.85M | |
$3,871,238 | 10 | -30.38% | $113.76M | |
$13,919,584 | 9 | -30.43% | $101.37M | |
$6,593,243 | 8 | 12.72% | $108.7M | |
$68,692,148 | 6 | -39.10% | $112.39M | |
$58,352 | 4 | -43.78% | $102.38M | |
$401,951 | 4 | 57.41% | $104.88M | |
$73,632,168 | 3 | -63.24% | $108.56M | |
$20,020,000 | 1 | -75.24% | $102.75M | |
$3,620 | 1 | 94.16% | $111.61M |
FATE Institutional Investors: Active Positions
| Increased Positions | 77 | +37.02% | 13M | +10.64% |
| Decreased Positions | 88 | -42.31% | 24M | -20.49% |
| New Positions | 33 | New | 5M | New |
| Sold Out Positions | 40 | Sold Out | 9M | Sold Out |
| Total Postitions | 197 | -5.29% | 106M | -9.85% |
FATE Ownership Change vs Market
Institutional Investor Ownership
| Redmile Group, Llc | $12,126.00 | 11.19% | 12.87M | -296,111 | -2.25% | 2024-12-31 |
| Blackrock, Inc. | $10,307.00 | 9.51% | 10.94M | +468,332 | +4.47% | 2024-12-31 |
| Vanguard Group Inc | $9,734.00 | 8.99% | 10.33M | -71,090 | -0.68% | 2024-12-31 |
| Boxer Capital, Llc | $4,673.00 | 4.31% | 4.96M | -3M | -39.62% | 2024-09-30 |
| Bellevue Group Ag | $4,559.00 | 4.21% | 4.84M | 0 | 0% | 2024-12-31 |
| Citadel Advisors Llc | $4,128.00 | 3.81% | 4.38M | +100,180 | +2.34% | 2024-12-31 |
| Deerfield Management Company, L.P. (Series C) | $3,350.00 | 3.09% | 3.56M | 0 | 0% | 2024-12-31 |
| Johnson & Johnson | $3,183.00 | 2.94% | 3.38M | 0 | 0% | 2024-12-31 |
| Baker Bros. Advisors Lp | $3,069.00 | 2.83% | 3.26M | +260,630 | +8.69% | 2024-12-31 |
| Ecor1 Capital, Llc | $2,873.00 | 2.65% | 3.05M | +3M | New | 2024-12-31 |